WGS analyst estimates
GeneDx (WGS) analyst ratings, the average price target and its range, and every firm's latest call.
WGS analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 1, 2026 | Guggenheim | GeneDx price target raised to $83 from $74 at Guggenheim | $83.00 |
| Aug 4, 2026 | Canaccord Genuity | GeneDx (WGS) PT Raised to $90 at Canaccord | $90.00 |
| Jun 29, 2026 | Guggenheim | GeneDx price target raised to $74 from $70 at Guggenheim | $74.00 |
| Jun 23, 2026 | Piper Sandler | GeneDx price target raised to $63 from $50 at Piper Sandler | $63.00 |
| May 5, 2026 | Wells Fargo | GeneDx price target lowered to $75 from $155 at Wells Fargo | $75.00 |
| May 5, 2026 | Canaccord Genuity | GeneDx price target lowered to $75 from $100 at Canaccord | $75.00 |
| May 5, 2026 | Guggenheim | GeneDx price target lowered to $70 from $100 at Guggenheim | $70.00 |
| May 5, 2026 | BTIG | GeneDx price target lowered to $90 from $170 at BTIG, removed from Top Picks | $90.00 |
| May 5, 2026 | Craig-Hallum | GeneDx price target lowered to $85 from $153 at Craig-Hallum | $85.00 |
| Apr 20, 2026 | Canaccord Genuity | GeneDx price target raised to $100 from $70 at Canaccord | $100.00 |
| Feb 24, 2026 | Piper Sandler | GeneDx price target lowered to $130 from $160 at Piper Sandler | $130.00 |
| Feb 24, 2026 | BTIG | GeneDx price target lowered to $170 from $200 at BTIG | $170.00 |
| Feb 23, 2026 | Jefferies | GeneDx price target lowered to $150 from $180 at Jefferies | $150.00 |
| Dec 22, 2025 | Canaccord Genuity | GeneDx price target raised to $170 from $160 at Canaccord | $170.00 |
| Dec 15, 2025 | Wells Fargo | GeneDx price target raised to $155 from $140 at Wells Fargo | $155.00 |
- 5 firms rate WGS: 5 buy, 0 hold, 0 sell.
- The average price target is $78.67 from 3 analysts, from $63.00 to $90.00.
Updated 2026-11-07 11:50 UTC